1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028

  • May 2022
  • 240 pages
  • ID: 6273080
  • Format: PDF
  • Kuick Research


Table of Contents

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 Report Highlights:

• Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
• Commercially Available PARP inhibitors: > 5 Drugs
• Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials
• Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
• Market Indicators Till 2028
• Approved Drugs Dosage, Sales, Patent, Price Insight
• Approved Drugs Sales Forecast Till 2028
• Global & Regional Market Analysis
• Regional Analysis Based On Drug Approvals: US, Europe, Chna & Japan

Genomic studies have revealed that altered DNA damage response (DDR) is an emerging hallmark and enabling characteristic of cancer, associated with both tumor initiation and progression. In addition, as anti-cancer cytotoxic agents such as chemotherapy and radiation function to induce DNA damage in cancer cells, alterations in DDR have role in resistance to these therapies. Therefore, scientists believed that targeting of DDR will significantly improve treatment and survival of cancer patients. One prominent DDR family of proteins which is being investigated is poly (ADP-ribose) polymerase (PARP) enzymes which have emerged as potential therapeutic target for the management of cancer.

Scientists have developed several PARP inhibitors which work by binding to the catalytic domain of the PARP enzyme. PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) are currently approved as a monotherapy by US FDA and EMA. Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer. In addition to this, a large number of PARP inhibitors are present in clinical development which is expected to gain approval during the forecast period.

For instance, Senaparib (IMP4297) developed by Impact Therapeutics is an investigational agent which works by targeting PARP (poly-ADP ribose polymerase). The company is currently conducting two phase-1 trials of senaparib in China and Australia. Till date, about 100 patients have been treated with Senaparib and initial results have demonstrated encouraging response. In comparison to other PARP inhibitors currently on the market and in clinical trials; senaparib has a wider therapeutic window and a better safety profile. This potentially makes senaparib more suitable for patients taking the drug chronically such as in maintenance therapy. Moreover, researchers believed that the combination of senaparib with other cancer targeting agents will also demonstrate promising results. Therefore, senaparib has the potential to be the best-in-class PARP inhibitor in the forthcoming years.

Apart from its role as monotherapy, PARP inhibitors have also shown to be promising in combination with other therapeutics including immunotherapy, PI3K, MEK and CDK 4/6 inhibitors. Furthermore, studies have revealed that combining PARP inhibitors with DNA damaging agents including chemotherapy and radiotherapy could prevent repair of treatment induced damage. These approaches have been widely investigated in ovarian and breast cancer. The coming years is expected to witness dominance of combinational therapy in PARP inhibitors market owing to its enhanced efficacy, specificity, and targetability in the management of wide range of cancers.

As per our report findings, the global PARP inhibitor market is expected to surpass US$ 6 Billion by 2028. Several factors including rising geriatric population with increased risk of developing cancer, increasing emphasis on research and development, and large number of ongoing clinical trials are the major factors boosting the growth of market. Further, favorable government policies for life science companies and government funding are also expected to boost the PARP inhibitor therapy demand in near future.

The Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors. The report provides in-depth analysis on the globally approved PARP inhibitors along with their patent expiration, pricing, dosage, sales analysis, and forecast. It also gives a detailed description of drivers and opportunities in PARP Inhibitor market that helps the consumers and potential customers to get a clear vision and take effective decisions. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Automated Liquid Handling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

  • $ 2499
  • April 2022
  • 145 pages

The global automated liquid handling market reached a value of US$ 910.1 Million in 2021. Looking forward, the analyst expects the market to reach a value of US$ 1,501.4 Million by 2027, exhibiting a CAGR ...

  • World
  • Drug Development
  • Genomics
  • Industry analysis
  • Employment Costs


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on